Applied DNA Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine & Adeno-Associated Virus ...
November 02 2020 - 8:00AM
Business Wire
– Company also Secures Follow-on Order from
Existing Contract Research Customer for Adoptive Cell Therapy (CAR
T) Application –
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the
"Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing, announced that it received orders for its linear DNA
to be evaluated in an RNA vaccine and Adeno-Associated Virus (AAV)
production from two new contract research customers, respectively.
The Company also received a follow-on order for linear DNA from an
existing contract research customer for a preclinical CAR T
therapy. The follow-on order marks the third order from the
existing customer for use across multiple applications. All orders
are to be shipped by the end of calendar 2020.
Applied DNA’s unique large-scale PCR production of linear DNA is
made capable by its LinearDNA™ platform, a proprietary process that
enables large, gram-scale production of single- or double-stranded
DNA for diagnostics; therapeutics, such as CAR T; vaccines, such as
those made of RNA and DNA; and improves the agility of virus
production, such as AAV. Some COVID-19 vaccines utilize AAV as the
vector for delivery of a synthetic gene that causes the transfected
cell to release antigens that promote immunity to SARS-CoV-2. The
Company announced in August 2020 that it filed a new U.S. patent
application for the manufacture of AAV via its LinearDNA™
platform.
“Our LinearDNA manufacturing platform is paving a new path for
nucleic acid-based drug development that, to date, is largely
reliant on plasmid-based production that is lengthy, prone to toxin
contamination, promulgating antibiotic resistance, accidental
inclusion of non-target DNA, and genomic integration. To our
knowledge, we are the only company to pursue the commercialization
of linear DNA for diagnostic and therapeutic applications via
large-scale PCR. We believe this makes us applicable to every
preclinical or clinical nucleic acid-based drug production program
being pursued by the industry’s leading companies. The addition of
new development customers and repeat orders for linear DNA, we
believe, suggests a growing appetite for a market-ready alternative
to plasmids,” stated Dr. James A. Hayward, president and CEO,
Applied DNA.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping, and pre-clinical nucleic acid-based
therapeutic drug candidates.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN’, and its publicly traded warrants are listed on OTC
under ticker symbol ‘APPDW’.
Applied DNA is a member of the Russell Microcap® Index.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to its history of
net losses, limited financial resources, limited market acceptance,
the uncertainties inherent in research and development, future
clinical data and analysis, including whether any of Applied DNA’s
or its partner’s diagnostic or therapeutic candidates will advance
further in the preclinical research or clinical trial process,
including receiving clearance from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies to conduct
clinical trials and whether and when, if at all, they will receive
final approval from the U.S. FDA or equivalent foreign regulatory
agencies, the fact that there has never been a commercial drug
product utilizing PCR-produced DNA technology approved for
therapeutic use, the unknown outcome of any applications to U.S.
FDA or equivalent foreign regulatory agencies, , and various other
factors detailed from time to time in Applied DNA’s SEC reports and
filings, including our Annual Report on Form 10-K filed on December
12, 2019 and our subsequent quarterly reports on Form 10-Q filed on
February 6, 2020, May 14, 2020 and August 6, 2020, and other
reports we file with the SEC, which are available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events, unless otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201102005294/en/
Investor contact: Sanjay M. Hurry, Applied DNA Sciences,
917-733-5573, sanjay.hurry@adnas.com Program contact: Brian
Viscount, Applied DNA Sciences, 631-240-8877,
brian.viscount@adnas.com Web: www.adnas.com Twitter:
@APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Sep 2023 to Sep 2024